About: Nivolumab/relatlimab

An Entity of Type: combination drug, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma. It contains nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody. It is given by intravenous infusion. The combination was approved for medical use in the United States in March 2022, and in the European Union in September 2022.

Property	Value
dbo:abstract	Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma. It contains nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody. It is given by intravenous infusion. The combination was approved for medical use in the United States in March 2022, and in the European Union in September 2022. (en)
dbo:alternativeName	Opdualag (en)
dbo:kegg	D12334
dbo:license	dbr:Nivolumab dbr:Relatlimab
dbo:wikiPageExternalLink	https://druginfo.nlm.nih.gov/drugportal/name/Nivolumab https://druginfo.nlm.nih.gov/drugportal/name/relatlimab
dbo:wikiPageID	70348402 (xsd:integer)
dbo:wikiPageLength	8103 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1123137155 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Melanoma dbr:Committee_for_Medicinal_Products_for_Human_Use dbr:European_Medicines_Agency dbr:Nivolumab dbc:Antineoplastic_drugs dbc:Combination_drugs dbc:Bristol_Myers_Squibb dbc:Monoclonal_antibodies_for_tumors dbr:Relatlimab dbr:Lymphocyte-activation_gene_3 dbr:Programmed_cell_death_protein_1 dbr:Intravenous dbr:Intravenous_infusion dbr:Fixed-dose_combination dbr:Indicated
dbp:atcPrefix	None (en)
dbp:class	Lymphocyte activation gene-3 blocking antibody (en) Programmed death receptor-1 blocking antibody (en)
dbp:component	Nivolumab (en) Relatlimab (en)
dbp:dailymedid	Nivolumab and relatlimab (en)
dbp:kegg	D12334 (en)
dbp:legalAu	S4 (en)
dbp:legalEu	Rx-only (en)
dbp:legalUs	Rx-only (en)
dbp:routesOfAdministration	dbr:Intravenous
dbp:tradename	Opdualag (en)
dbp:type	combo (en)
dbp:wikiPageUsesTemplate	dbt:Antineoplastic-drug-stub dbt:Cite_journal dbt:Cite_web dbt:Infobox_drug dbt:Portal_bar dbt:Reflist dbt:Use_American_English dbt:Use_dmy_dates dbt:ClinicalTrialsGov dbt:Monoclonals_for_immune_system dbt:Targeted_cancer_therapeutic_agents
dcterms:subject	dbc:Antineoplastic_drugs dbc:Combination_drugs dbc:Bristol_Myers_Squibb dbc:Monoclonal_antibodies_for_tumors
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:CombinationDrug dbo:Drug
rdfs:comment	Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma. It contains nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody. It is given by intravenous infusion. The combination was approved for medical use in the United States in March 2022, and in the European Union in September 2022. (en)
rdfs:label	Nivolumab/relatlimab (en)
owl:sameAs	wikidata:Nivolumab/relatlimab https://global.dbpedia.org/id/GSCXT
prov:wasDerivedFrom	wikipedia-en:Nivolumab/relatlimab?oldid=1123137155&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:Nivolumab/relatlimab
is dbo:wikiPageRedirects of	dbr:Opdualag
is dbo:wikiPageWikiLink of	dbr:Melanoma dbr:Opdualag dbr:Nivolumab dbr:Relatlimab
is foaf:primaryTopic of	wikipedia-en:Nivolumab/relatlimab